KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Profit After Tax (2016 - 2025)

Historic Profit After Tax for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $152000.0.

  • TherapeuticsMD's Profit After Tax rose 12495.89% to $152000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $171000.0, marking a year-over-year increase of 10504.28%. This contributed to the annual value of -$2.3 million for FY2024, which is 7750.54% up from last year.
  • TherapeuticsMD's Profit After Tax amounted to $152000.0 in Q3 2025, which was up 12495.89% from $551000.0 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Profit After Tax registered a high of $159.4 million during Q4 2022, and its lowest value of -$49.0 million during Q1 2022.
  • For the 5-year period, TherapeuticsMD's Profit After Tax averaged around $454789.5, with its median value being -$1.1 million (2024).
  • As far as peak fluctuations go, TherapeuticsMD's Profit After Tax surged by 47098.7% in 2022, and later crashed by 10215.0% in 2023.
  • Quarter analysis of 5 years shows TherapeuticsMD's Profit After Tax stood at -$43.0 million in 2021, then skyrocketed by 470.99% to $159.4 million in 2022, then plummeted by 100.55% to -$883000.0 in 2023, then soared by 113.7% to $121000.0 in 2024, then grew by 25.62% to $152000.0 in 2025.
  • Its Profit After Tax was $152000.0 in Q3 2025, compared to $551000.0 in Q2 2025 and -$653000.0 in Q1 2025.